natgillin/translations-raw huggingface dataset:
400 mg og 800 mg tabletter anvendes til at behandle voksne og børn (fra 3 år og opefter med en legemsvægt på mindst 40 kg), som er smittet med hiv, og - som ikke før har fået medicin til behandling af hiv - hos nogle patienter, som før har fået medicin til behandling af hiv (din læge vil afgøre dette). 
400 and 800 milligram tablets are used to treat adults and children (3 years of age and above, at least 40 kilograms body weight) who are infected by HIV and who have not used antiretroviral medicines before.
ODIN er et randomiseret, åbent fase III-studie, der sammenligner darunavir/ritonavir 800/100 mg en gang dagligt med darunavir/ritonavir 600/100 mg to gange dagligt hos ART-erfarne hiv-1-inficerede patienter, hos hvem screening for genotype-resistens har vist, at der ikke fandtes darunavir RAMs (dvs. V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V, L89V), og screening for hiv-1- RNA viste > 1.000 kopier/ml. 
ODIN is a Phase III, randomised, open-label trial comparing darunavir/ritonavir 800/100 mg once daily versus darunavir/ritonavir 600/100 mg twice daily in ART-experienced HIV-1 infected patients with screening genotype resistance testing showing no darunavir RAMs (i.e. V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V, L89V) and a screening HIV-1 RNA > 1,000 copies/ml.
Dolutegravir dolutegravir AUC ↓ 22% dolutegravir C24t ↓ 38% dolutegravir Cmax ↓ 11% darunavir ↔* * Ved brug af historiske farmakokinetiske data på tværs af studier 
HIV ANTIRETROVIRALS Integrase strand transfer inhibitors Dolutegravir dolutegravir AUC ↓ 22% dolutegravir C24h ↓38% dolutegravir Cmax ↓ 11% darunavir ↔* * Using cross-study comparisons to historical pharmacokinetic data
ART-erfarne pædiatriske patienter (3 til 17 år og legemsvægt mindst 40 kg) Hos ART-erfarne patienter, der ikke har DRV-RAMs*, og som har plasma-hiv-1RNA < 100.000 kopier/ml og CD4+-celletal ≥ 100 x 10 
ART-experienced paediatric patients (3 to 17 years of age and weighing at least 40 kg) In ART-experienced patients without DRV-RAMs* and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 10
Hvis antidepressiva coadministreres med boostet darunavir, anbefales dosistitrering af det antidepressive lægemiddel ud fra en klinisk vurdering af antidepressivt respons. 
If antidepressants are co-administered with boosted darunavir, the recommended approach is a dose titration of the antidepressant based on a clinical assessment of antidepressant response.
Buprenorphin/naloxon 8/2 mg-16/4 mg en gang daglig buprenorphin AUC ↓ 11% buprenorphin Cmin ↔ buprenorphin Cmax ↓ 8% norbuprenorphin AUC ↑ 46% norbuprenorphin Cmin ↑ 71% norbuprenorphin Cmax ↑ 36% naloxon AUC ↔ naloxon Cmin ND naloxon Cmax ↔ 
Buprenorphine/naloxone 8/2 mg-16/4 mg once daily buprenorphine AUC ↓ 11% buprenorphine Cmin ↔ buprenorphine Cmax ↓ 8% norbuprenorphine AUC ↑ 46% norbuprenorphine Cmin ↑ 71% norbuprenorphine Cmax ↑ 36% naloxone AUC ↔ naloxone Cmin ND naloxone Cmax ↔
400 mg og 800 mg tabletter kan anvendes til at sammensætte regimet med 800 mg en gang dagligt. 
400 mg and 800 mg tablets can be used to construct the once daily 800 mg regimen.
Klinisk monitorering anbefales ved co-administration af darunavir med lavdosis ritonavir og disse antidepressiva, og det kan være nødvendigt at justere dosis af antidepressivummet. 
Clinical monitoring is recommended when co-administering darunavir with low dose ritonavir with these antidepressants and a dose adjustment of the antidepressant may be needed.
er 800 mg (2 tabletter a 400 mg Darunavir Krka d.d. 
is 800 milligram (2 tablets containing 400 milligram of Darunavir Krka d.d.
Co-administration af darunavir coadministreret med cobicistat og rifabutin frarådes. 
Co-administration of darunavir coadministered with cobicistat and rifabutin is not recommended.
Alfentanil metabolisees via CYP3A og kan dermed hæmmes af darunavir administreret sammen med lavdosis ritonavir. 
The metabolism of alfentanil is mediated via CYP3A, and may as such be inhibited by darunavir co-administered with low dose ritonavir.
ANTIBIOTIKA Clarithromycin 500 mg to gange daglig clarithromycin AUC ↑ 57% clarithromycin Cmin ↑ 174% clarithromycin Cmax ↑ 26% #darunavir AUC ↓ 13% #darunavir Cmin ↑ 1% #darunavir Cmax ↓ 17% 14-OH-clathromycinkoncentrationenerne var ikke målbare ved kombination med darunavir/ritonavir. 
ANTIBIOTIC Clarithromycin 500 mg twice daily clarithromycin AUC ↑ 57% clarithromycin Cmin ↑ 174% clarithromycin Cmax ↑ 26% darunavir AUC ↓ 13% darunavir Cmin ↑ 1% darunavir Cmax ↓ 17% 14-OH-clarithromycin concentrations were not detectable when combined with darunavir/ritonavir.
Nevirapin 200 mg to gange daglig nevirapin AUC ↑ 27% nevirapin Cmin ↑ 47% nevirapin Cmax ↑ 18% #darunavir: koncentrationerne var i overensstemmelse med historiske data. 
Nevirapine 200 mg twice daily nevirapine AUC ↑ 27% nevirapine Cmin ↑ 47% nevirapine Cmax ↑ 18% darunavir: concentrations were consistent with historical data (↑ nevirapine from CYP3A inhibition)
- Kortikosteroider, herunder betamehtason, budesonid, fluticason, mometason, prednison, triamcinolon. 
Corticosteroids including bethametasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone.
Plasmakoncentrationen af lovastatin og simvastatin forventes at stige markant, når de gives sammen med darunavir co-administreret med lavdosis ritonavir. 
Lovastatin and simvastatin are expected to have markedly increased plasma concentrations when coadministered with darunavir coadministered with low dose ritonavir.
TLOVR non-VF censureret algoritme baseret på hiv-1-RNA <50 kopier/ml med undtagelse af TITAN (hiv-1RNA <400 kopier/ml) IAS-USA-lister 
TLOVR non-VF censored algorithm based on HIV-1 RNA < 50 copies/ml, except for TITAN (HIV-1 RNA < 400 copies/ml)
Co-administration af darunavir og ritonavir med andre lægemidler, som hæmmer CYP3A, kan nedsætte clearance af darunavir og ritonavir, hvilket kan medføre øgede plasmakoncentrationer af darunavir og ritonavir (f.eks. indinavir, azolantimykotika som clotrimazol). 
Co-administration of darunavir and ritonavir and other medicinal products that inhibit CYP3A may decrease the clearance of darunavir and ritonavir and may result in increased plasma concentrations of darunavir and ritonavir (e.g. indinavir azole antifungals like clotrimazole).
Med CD4+celletal (×10 
With Baseline CD4+ cell count (x 10
600 mg Darunavir Krka d.d. 
600 milligram Darunavir Krka d.d.
Det skal du vide, før du begynder at tage Darunavir Krka d.d. 
What you need to know before you take Darunavir Krka d.d.
600 mg en gang daglig efavirenz AUC ↑ 21% efavirenz Cmin ↑ 17% efavirenz Cmax ↑ 15% #darunavir AUC ↓ 13% #darunavir Cmin ↓ 31% #darunavir Cmax ↓ 15% (↑ efavirenz fra CYP3A-hæmning) (↓ darunavir fra CYP3A-induktion) 
600 mg once daily efavirenz AUC ↑ 21% efavirenz Cmin ↑ 17% efavirenz Cmax ↑ 15% darunavir AUC ↓ 13% darunavir Cmin ↓ 31% darunavir Cmax ↓ 15% (↑ efavirenz from CYP3A inhibition) (↓ darunavir from CYP3A induction)
Klinisk monitorering anbefales, når boostet darunavir administreres sammen med lavdosis ritonavir og clonazepam. 
Clinical monitoring is recommended when co-administering darunavir with low dose ritonavir and clonazepam.
Hvis du har glemt at tage Darunavir Krka d.d. 
If you forget to take Darunavir Krka d.d.
- fesoterodin, solifenacin(til behandling af sygdomme i urinvejene). 
Fesoterodine, solifenacin(to treat urologic disorders).
- Fesoterodin, solifenacin (til behandling af sygdomme i urinvejene). 
Fesoterodine, solifenacin (to treat urologic disorders).
Med hiv-RNA <100.000 ved baseline Med hiv-RNA 
With baseline HIV-RNA ≥
Dosis til børn fra 3 år og opefter med en legemsvægt på mindst 40 kg, som ikke tidligere har fået medicin mod hiv-infektion (barnets læge vil afgøre dette) - Den sædvanlige dosis af Darunavir Krka d.d. 
Dose for children 3 years of age and above, weighing more than 40 kilograms who have not taken antiretroviral medicines before (your child's doctor will determine this) The usual dose of Darunavir Krka d.d.
≥30 kg-<40 kg 675 mg darunavir/100 mg ritonavir en gang dagligt 
≥ 30 kg-< 40 kg 675 mg darunavir/100 mg ritonavir once daily
eller 
OR
Da digoxin har et snævert terapeutisk indeks, anbefales det at starte med at udskrive den lavest mulige dosis digoxin, hvis der skal gives digoxin til patienter i behandling med darunavir/ritonavir. 
that the lowest possible dose of digoxin should initially be prescribed in case digoxin is given to patients on darunavir/ritonavir therapy.
Lopinavir/ritonavir 533/133,3 mg to gange daglig lopinavir AUC ↑ 9% lopinavir Cmin ↑ 23% lopinavir Cmax ↓ 2% darunavir AUC ↓ 38%‡ darunavir Cmin ↓ 51%‡ darunavir Cmax ↓ 21%‡ lopinavir AUC ↔ lopinavir Cmin ↑ 13% lopinavir Cmax ↑ 11% darunavir AUC ↓ 41% darunavir Cmin ↓ 55% darunavir Cmax ↓ 21% ‡ baseret på ikkedosisnormaliserede værdier 
Lopinavir/ritonavir 533/133.3 mg twice daily lopinavir AUC ↑ 9% lopinavir Cmin ↑ 23% lopinavir Cmax ↓ 2% darunavir AUC ↓ 38% darunavir Cmin ↓ 51% darunavir Cmax ↓ 21% lopinavir AUC ↔ lopinavir Cmin ↑ 13% lopinavir Cmax ↑ 11% darunavir AUC ↓ 41% darunavir Cmin ↓ 55% darunavir Cmax ↓ 21% based upon non dose normalised values
4.3 og 4.4). 
section 4.3).
100 mg ritonavir oral opløsnig: 80 mg/ml 
100 milligram ritonavir oral solution: 80 milligram per millilitre
400 mg filmovertrukne tabletter Darunavir Krka d.d. 
400 mg film-coated tablets Darunavir Krka d.d.
400 mg filmovertrukne tabletter er tilgængelige i beholdere indeholdende 30 filmovertrukne tabletter (1 beholder med 30 filmovertrukne tabletter), 60 filmovertrukne tabletter (2 beholdere med 30 filmovertrukne tabletter), 90 filmovertrukne tabletter (3 beholdere med 30 filmovertrukne tabletter) og 180 filmovertrukne tabletter (6 beholdere med 30 filmovertrukne tabletter) i en æske. 
400 mg film-coated tablets are available in bottles containing 30 film-coated tablets (1 bottle of 30 film-coated tablets), 60 film-coated tablets (2 bottles of 30 film-coated tablets), 90 film-coated tablets (3 bottles of 30 film-coated tablets) and 180 film-coated tablets (6 bottles of 30 film-coated tablets) in a box.
Koncentrationerne af disse lægemidler kan øges ved coadministration med darunavir og lavdosis ritonavir, hvilket kan øge risikoen for de bivirkninger, der normalt ses med disse midler. 
Concentrations of these medicinal products may be increased when coadministered with darunavir with low dose ritonavir resulting in the potential for increased adverse events usually associated with these agents.
4.5) - sildenafil - ved behandling af pulmonal arteriel hypertension, avanafil - simvastatin, lovastatin og lomitapid (se pkt. 
see section 4.5) sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil simvastatin, lovastatin and lomitapide (see section 4.5) dabigatran, ticagrelor (see section 4.5).
Darunavir Krka d.d., administreret sammen med lavdosis ritonavir, er i kombination med andre antiretrovirale lægemidler indiceret til behandling af patienter med human immundefektvirus (hiv-1)-infektion. 
Darunavir Krka d.d., co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection.
Nogle typer medicin må du ikke tage sammen med Darunavir Krka d.d.. 
There are some medicines that you must not combine with Darunavir Krka d.d..
er tilgængelig i beholdere indeholdende 30 filmovertrukne tabletter (1 beholder med 30 filmovertrukne tabletter), 60 filmovertrukne tabletter (2 beholdere med 30 filmovertrukne tabletter), 90 filmovertrukne tabletter (3 beholdere med 30 filmovertrukne tabletter) og 180 filmovertrukne tabletter (6 beholdere med 30 filmovertrukne tabletter) i en æske. 
is available in bottles containing 30 film-coated tablets (1 bottle of 30 film-coated tablets), 60 film-coated tablets (2 bottles of 30 film-coated tablets), 90 film-coated tablets (3 bottles of 30 film-coated tablets) and 180 film-coated tablets (6 bottles of 30 film-coated tablets) in a boxes.
Dosis er enten: - 800 mg Darunavir Krka d.d. 
The dose is either: 800 milligram Darunavir Krka d.d.
Samtidig administration af boostet darunavir og dabigatran eller ticagrelor er kontraindiceret (se pkt. 
Concomitant administration of boosted darunavir with dabigatran or ticagrelor is contraindicated (see
digoxin Cmax ↑ 29% (↑ digoxin fra en sandsynlig hæmning af P-gp) 
Given that digoxin has a narrow therapeutic index, it is recommended digoxin Cmax ↑ 29% (↑ digoxin from probable inhibition of Pgp)
- Barnet skal tage Darunavir Krka d.d. 
The child must take Darunavir Krka d.d.
rosuvastatin AUC ↑ 48%║ rosuvastatin Cmax ↑ 144%║ 
Rosuvastatin 10 mg once daily rosuvastatin AUC ↑ 48% rosuvastatin Cmax ↑ 144%
4.4, hvis kreatinin-clearance benyttes ved dosisjustering af emtricitabin disse lægemidler og boostet darunavir. 
Refer to section 4.4 if creatinine clearance is used for dose adjustment of emtricitabine or lamivudine.
Carbamazepin AUC ↑ 45% Carbamazepin Cmin ↑ 54% Carbamazepin Cmax ↑ 43% 
Carbamazepine 200 mg twice daily carbamazepine AUC ↑ 45% carbamazepine Cmin ↑ 54% carbamazepine Cmax ↑ 43% darunavir AUC ↔ darunavir Cmin ↓ 15% darunavir Cmax ↔
(2 tabletter a 400 mg Darunavir Krka d.d. 
(2 tablets containing 400 milligram of Darunavir Krka d.d.
Saquinavir: sammenligning af saquinavir/ritonavir 1.000/100 mg to gange daglig vs saquinavir/darunavir/ritonavir 1.000/400/100 mg to gange daglig Darunavir :sammenligning af darunavir/ritonavir 400/100 mg to gange daglig vs darunavir/ritonavir 400/100 mg to gange daglig i kombination med saquinavir 1.000 mg to gange daglig. 
Saquinavir: comparison of saquinavir/ritonavir 1,000/100 mg twice daily vs. saquinavir/darunavir/ritonavir 1,000/400/100 mg twice daily Darunavir: comparison of darunavir/ritonavir 400/100 mg twice daily vs. darunavir/ritonavir 400/100 mg in combination with saquinavir 1,000 mg twice daily.
ethinylestradiol Cmax  14 % med darunavir/cobicistat ethinylestradiol AUC ↓ 44% ethinylestradiol Cmin ↓ 62% ethinylestradiol Cmax ↓ 32% norethindron AUC ↓ 14% norethindron Cmin ↓ 30% 
ethinylestradiol Cmax  14% with darunavir/cobicistat ethinylestradiol AUC ↓ 44% ethinylestradiol Cmin ↓ 62% ethinylestradiol Cmax ↓ 32% norethindrone AUC ↓ 14% norethindrone Cmin ↓ 30% norethindrone Cmax ↔ with darunavir/ritonavir
Samtidig anvendelse af sildenafil eller tadalafil til behandling af pulmonal arteriel hypertension og darunavir co-administreret med lavdosis ritonavir kan øge plasmakoncentrationen af sildenafil og tadalafil. 
Concomitant use of sildenafil or tadalafil for the treatment of pulmonary arterial hypertension and darunavir coadministered with low dose ritonavir may increase plasma concentrations of sildenafil or tadalafil.
ethinylestradiol AUC ↓ 44% ethinylestradiol Cmin ↓ 62% ethinylestradiol Cmax ↓ 32% norethindron AUC ↓ 14% norethindron Cmin ↓ 30% norethindron Cmax ↔ 
ethinylestradiol AUC ↓ 44% ethinylestradiol Cmin ↓ 62% ethinylestradiol Cmax ↓ 32% norethindrone AUC ↓ 14% norethindrone Cmin ↓ 30% norethindrone Cmax ↔ with darunavir/ritonavir
4.2): - til behandling af hiv-1-infektion hos voksne patienter, som tidligere har været i antiretroviral behandling (ART-erfarne), inklusive patienter, der tidligere har fået omfattende præmedicinering - til behandling af hiv-1-infektion hos pædiatriske patienter fra 3 år med en legemsvægt på mindst 15 kg. 
• For the treatment of HIV-1 infection in antiretroviral treatment (ART)-experienced adult patients, including those that have been highly pre-treated.
(CYP3A, CYP2D6 og/eller P-gphæmning) 
(CYP3A, CYP2D6 and/or P-gp inhibition)
Co-administration af darunavir coadministreret med cobicistat og bosentan frarådes. 
Co administration of darunavir coadministered with cobicistat and bosentan is not recommended.
Se doseringsanbefalingerne til ART-naive patienter se produktresuméet for Darunavir Krka d.d. 
For dosage recommendations in ART-naïve patients see the Summary of Product Characteristics for Darunavir Krka d.d.
tenofovir AUC ↑ 22% tenofovir Cmin ↑ 37% tenofovir Cmax ↑ 24% #darunavir AUC ↑ 21% #darunavir Cmin ↑ 24% #darunavir Cmax ↑ 16% (↑ tenofovir fra effekten på MDR-1 transport i de renale tubuli) 
Tenofovir disoproxil 245 mg once daily tenofovir AUC ↑ 22% tenofovir Cmin ↑ 37% tenofovir Cmax ↑ 24% darunavir AUC ↑ 21% darunavir Cmin ↑ 24% darunavir Cmax ↑ 16% (↑ tenofovir from effect on MDR-1 transport in the renal tubules)
Co-administration af parenteral midazolam med boostet darunavir kan give en kraftig forøgelse af koncentrationen af dette benzodiazepin. 
If parenteral midazolam is co-administered with boosted darunavir it may cause a large increase in the concentration of this benzodiazepine.
En dosis ritonavir a er mellem 15 og 30 kg 
One ritonavir a dose is between 15 and 30 kilograms 600 milligram
Baseret på teoretiske overvejelser forventes co-administreret boostet darunavir at øge eksponeringen for lomitapid. 
Based on theoretical considerations boosted darunavir is expected to increase the exposure of lomitapide when coadministered.
knogleskørhed - nedsættelse af skjoldbruskkirtlens funktion.Dette kan ses ved en blodprøve - forhøjet blodtryk, rødme - røde eller tørre øjne - feber, hævede ben på grund af væske, utilpashed, irritabilitet, smerte - symptomer på infektion, herpes simplex - impotens, større bryster - søvnproblemer, søvnighed, depression, angst, unormale drømme, nedgang i seksuallyst. 
This can be seen in a blood test. high blood pressure, flushing red or dry eyes fever, swelling of lower limbs due to fluids, malaise, irritability, pain symptoms of infection, herpes simplex erectile dysfunction, enlargement of breasts sleeping problems, sleepiness, depression, anxiety, abnormal dreams, decrease in sexual drive
800 mg filmovertrukne tabletter (tabletter): 
800 mg film-coated tablets (tablets):
Indinavir 800 mg to gange daglig indinavir AUC ↑ 23% indinavir Cmin ↑ 125% indinavir Cmax ↔ #darunavir AUC ↑ 24% #darunavir Cmin ↑ 44% #darunavir Cmax ↑ 11% 
Indinavir 800 mg twice daily indinavir AUC ↑ 23% indinavir Cmin ↑ 125% indinavir Cmax ↔ darunavir AUC ↑ 24% darunavir Cmin ↑ 44% darunavir Cmax ↑ 11%
De filmovertrukne tabletter (tabletter) er orange-brune, ovale, bikonvekse, indgraveret med mærket S2 på den ene side. 
looks like and contents of the pack Film-coated tablets (tablets) are orangish brown, oval, biconvex, engraved with a mark S2 on one side.
- Barnet skal tage den beregnede dosis af Darunavir Krka d.d. 
The child must take the appropriate doses of Darunavir Krka d.d.
600 mg darunavir/100 mg ritonavir to gange dagligt ritonavir oral opløsning: 80 mg/ml 
600 mg darunavir/100 mg ritonavir twice daily ritonavir oral solution: 80 mg/ml
Virkningen af Darunavir Krka d.d. 
The effects of Darunavir Krka d.d.
Hver filmovertrukken tablet indeholder 400 mg eller 800 mg darunavir. 
Each film-coated tablet contains 400mg or 800mg darunavir.
Darunavir Krka d.d., co-administreret med cobicistat, er i kombination med andre antiretrovirale lægemidler indiceret til behandling af human immundefektvirus (hiv1)-infektion hos voksne patienter (se pkt. 
Darunavir Krka d.d., co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection in adult patients (see section 4.2).
eller 1 tablet a 800 mg Darunavir Krka d.d.) 
or 1 tablet containing 800 milligram of Darunavir Krka d.d.)
Hvad er Darunavir Krka d.d. 
What is Darunavir Krka d.d.
For dosisanbefalinger til børn se produktresuméet for Darunavir Krka d.d. 
For dosage recommendations in children, see the Summary of Product Characteristics for Darunavir Krka d.d.
Der skal udvises forsigtighed ved samtidig brug af andre PDE-5hæmmere til behandling af erektil dysfunktion og darunavir administreret sammen med lavdosis ritonavir. 
Concomitant use of other PDE-5 inhibitors for the treatment of erectile dysfunction with darunavir coadministered with low dose ritonavir should be done with caution.
- Salmeterol (medicin til behandling af astma). 
Buprenorphine/naloxone (medicines to treat opioiddependence) Salmeterol (medicine to treat asthma)
Doseringen af anden medicin skal muligvis ændres, da behandlingsvirkningen eller bivirkninger af enten denne eller Darunavir Krka d.d. 
The dosage of other medicines might need to be changed since either their own or Darunavir Krkad.d.
30 filmovertrukne tabletter: EU/1/17/1248/009 90 filmovertrukne tabletter: EU/1/17/1248/010 
30 film-coated tablets: EU/1/17/1248/009 90 film-coated tablets: EU/1/17/1248/010
#darunavir AUC ↓ 26% #darunavir Cmin ↓ 42% #darunavir Cmax ↓ 17% saquinavir AUC ↓ 6% saquinavir Cmin ↓ 18% saquinavir Cmax ↓ 6% 
Saquinavir 1,000 mg twice daily darunavir AUC ↓ 26% darunavir Cmin ↓ 42% darunavir Cmax ↓ 17% saquinavir AUC ↓ 6% saquinavir Cmin ↓ 18% saquinavir Cmax ↓ 6%
10 kg til <15 kg N=5 
Darunavir/ritonavir 10 kg to < 15 kg N=5
Anvisninger for børn fra 3 år og opefter med en legemsvægt på mindst 40 kg - Tag hver dag 800mg DarunavirKrkad.d. 
Instructions for children 3 years of age and above, weighing more than 40 kilograms Take 800 milligram Darunavir Krka d.d.
EU/1/17/1248/009 30 filmovertrukne tabletter EU/1/17/1248/010 90 filmovertrukne tabletter 
EU/1/17/1248/009 30 film-coated tablets EU/1/17/1248/010 90 film-coated tablets
Opbevar lægemidlet utilgængeligt for børn. 
tablets is right for the child.
ANTIBIOTIKA Clarithromycin 500 mg to gange daglig clarithromycin AUC ↑ 57% clarithromycin Cmin ↑ 174% 
ANTIBIOTIC Clarithromycin 500 mg twice daily clarithromycin AUC ↑ 57% clarithromycin Cmin ↑ 174% clarithromycin Cmax ↑ 26% darunavir AUC ↓ 13% darunavir Cmin ↑ 1% darunavir Cmax ↓ 17%
Darunavir Krka d.d., administreret sammen med lavdosis ritonavir, er i kombination med andre antiretrovirale lægemidler indiceret til behandling af patienter med human immundefektvirus (hiv-1)-infektion (se pkt. 
Darunavir Krka d.d., co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection (see section 4.2).
kan blive påvirket, når de kombineres. 
'stherapeutic effect or side effects may be influenced when combined.
Effekt af darunavir 800 mg en gang dagligt co-administreret med 150 mg cobicistat en gang dagligt hos ART-naive og ART-erfarne patienter GS-US-216-130 er et enkeltarmet, åbent, fase III-studie, som evaluerer farmakokinetik, sikkerhed, tolerabilitet og effekt af darunavir med cobicistat hos 313 hiv-1-inficerede voksne patienter (295 behandlingsnaive og 18 behandlingserfarne). 
GS-US-216-130 is a single arm, open-label, Phase III trial evaluating the pharmacokinetics, safety, tolerability, and efficacy of darunavir with cobicistat in 313 HIV-1 infected adult patients (295 treatment-naïve and 18 treatment-experienced).
sammen med 150 mg cobicistat eller 100 mg ritonavir. 
always together with 150 milligram of cobicistat or100 milligram of ritonavir.
600 mg filmovertrukne tabletter 
600 mg film-coated tablets
Andre styrker af Darunavir Krka d.d. 
Other strengths of Darunavir Krka d.d.
Virkning af darunavir 800 mg en gang dagligt co-administreret med 100 mg ritonavir en gang dagligt hos ART-naive patienter 
Efficacy of darunavir 800 mg once daily co-administered with 100 mg ritonavir once daily in ARTexperienced patients
Silicificeret mikrokrystallinsk cellulose (Mikrokrystallinsk cellulose; Silica, kolloid vandfri) 
Silicified microcrystalline cellulose (Cellulose, microcrystalline; Silica, colloidal anhydrous) Magnesium stearate (E470b)
Dosis til voksne, som ikke tidligere har fået hiv-medicin (din læge vil afgøre dette) Du har brug for en anden dosis af Darunavir Krka d.d., som ikke kan sammensættes med 600 mg tabletterne. 
Dose for adults who have taken antiretroviral medicines before (your doctor will determine this) Maybe you will require a different dose of Darunavir Krka d.d.
Dosisjustering af buprenorphin er måske ikke nødvendig ved administration sammen med boostet darunavir, men en omhyggelig klinisk monitorering for tegn på opioidtoksicitet anbefales. 
administered with boosted darunavir but a careful clinical monitoring for signs of opiate toxicity is recommended.